OMAHA, Neb., March 5 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO), a leading global biotechnology company, announced today its Molecular Laboratory has received notification from the state of California it can begin offering its services in the state. Transgenomic expects to begin marketing their Molecular Laboratory services, including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases, to physicians in California immediately. Transgenomic also boasts a comprehensive portfolio of cytogenetics, FISH, IHC and histology diagnostics.
This California certification reinforces previous certifications awarded to Transgenomic's state-of-the-art testing facility. Transgenomic's Molecular Laboratory is a Good Laboratory Practices (GLP) compliant environment, is certified under the Clinical Laboratory Improvement Amendment (CLIA) as a high complexity lab, and is accredited by CAP (College of American Pathologists).
"The state of California represents the largest market opportunity in the United States for Transgenomic's Molecular Laboratory testing services," said Craig Tuttle, President and Chief Executive Officer of Transgenomic. "The state of California follows a rigorous certification process. Completing our California license not only allows us to penetrate this large market for our testing services but it is also a testament to the high quality standards of our laboratory services business."
Transgenomic is a global biotechnology company that provides unique products and services for automated high sensitivity genetic variation and mutation analysis. Their offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of Pharmacogenomics and personalized medicine. Specific offerings incl
|SOURCE Transgenomic, Inc.|
Copyright©2009 PR Newswire.
All rights reserved